(Print or Type Responses)

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
OMB Number:	3235-0287
Estimated average burd	en
hours per response	0.5

longer subject to Section 16. Form 4 or Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person – Goodman Daniel Wintner					2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]								S. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X. Director 10% Owner					
	NIX PHAR	(First) RMACEUTICAL STREET, SUITE		3. Da 05/1		Earliest Tra	ınsac	ction (M	onth/Day	/Year)			Officer (give tit	le below)		pecify below)		
(Street)					4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ For	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_ Form filed by One Reporting Person  Form filed by More than One Reporting Person					
	AM, NJ 07														8			
(Ci	ty)	(State)	(Zip)				Tal	ole I - N	on-Deriv	ative Securi	ties A	acquired, D	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea			Ex (ear) any	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		(A	4. Securities Acquire (A) or Disposed of ( (Instr. 3, 4 and 5)		(D) Owned Following Transaction(s)		curities Beneficially g Reported		wnership o	7. Nature of Indirect Beneficial		
			(M				Code	V Ar	(A) o		(Instr. )	str. 3 and 4)		or (I	Indirect (Ir	Ownership Instr. 4)		
			Table					tł c cquired	nis form urrently , Dispos		quired cont eficial	d to respo trol numb	ond unles er.		contained ir displays a	SEC 14	474 (9-02)	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) Execution D	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		able and	7. o: S	7. Title and Amou of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (Do or Indirect (I)	(Instr. 4)		
				Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Т		Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock	\$ 1.03	05/10/2021		A		270,882			(1	05/10/20		Common	270,882	\$ 0	270,882			

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Goodman Daniel Wintner C/O TONIX PHARMACEUTICALS HOLDING CORP. 26 MAIN STREET, SUITE 101 CHATHAM, NJ 07928	X						

# **Signatures**

/s/ Jessica Morris, Attorney-in-Fact	05/12/2021
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.